A phase II trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701

Rituximab combined with chemotherapy has improved the survival of previously untreated patients with follicular lymphoma (FL). Nevertheless, many patients neither want nor can tolerate chemotherapy, leading to interest in biological approaches. Epratuzumab is a humanized anti-CD22 monoclonal antibod...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Grant, Barbara W., Jung, Sin-Ho, Johnson, Jeffrey L., Kostakoglu, Lale, His, Eric, Byrd, John C., Jones, Jeffrey, Leonard, John P., Martin, S. Eric, Cheson, Bruce D.
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3828050/
https://ncbi.nlm.nih.gov/pubmed/23922187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28299
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items